Table 2 Baseline mean (SD) values of efficacy variables, adjusted mean changes from baseline to day 42 (least squares mean (standard error of mean)) and treatment effect (mean difference (95% CI) placebo minus CRx-102) in the intention to treat population

	Baseline		Changes		Treatment effect	p Value
	CRx-102 (n = 42)	Placebo (n = 41)	CRx-102	Placebo	Treatment effect	p Value
AUSCAN:
Pain	57.9 (20.2)	60.9 (19.4)	−14.2 (3.0)	−4.0 (3.1)	10.2 (1.6 to 18.7)	0.020
Physical	62.4 (19.5)	67.8 (17.5)	−8.1 (2.7)	−3.6 (2.7)	4.5 (−3.2 to 12.2)	0.246
Stiffness	61.1 (18.0)	64.5 (21.2)	−15.2 (3.2)	−7.7 (3.3)	7.5 (−1.7 to 16.7)	0.108
VAS:
Joint pain	58.3 (20.1)	62.1 (16.9)	−18.6 (3.3)	−6.3 (3.3)	12.3 (3.0 to 21.5)	0.010
Patient global	58.0 (19.5)	62.3 (17.9)	−15.9 (3.2)	−4.2 (3.3)	11.7 (2.5 to 20.8)	0.013
Lab tests:
CRP mg/litre	2.5 (2.9)	2.3 (2.2)	−0.2 (0.4)	0.1 (0.4)	0.3 (−0.7 to 1.4)	0.536
Joint counts:
Tender joints	9.5 (4.7)	9.4 (4.6)	−3.6 (0.7)	−2.4 (0.7)	1.2 (−0.9 to 3.2)	0.258
Soft tissue swelling	5.5 (4.7)	5.0 (4.4)	−2.4 (0.5)	−1.6 (0.5)	0.8 (−0.6 to 2.2)	0.262

AUSCAN, Australian/Canadian Osteoarthritis Hand Index; CRP, C-reactive protein; VAS, visual analogue scale.